Literature DB >> 15857854

Global gene expression as a function of germline genetic variation.

Deborah French1, Mark R Wilkinson, Wenjian Yang, Luc de Chaisemartin, Edwin H Cook, Soma Das, Mark J Ratain, William E Evans, James R Downing, Ching-Hon Pui, Mary V Relling.   

Abstract

Common, functional, germline genetic polymorphisms have been associated with clinical cancer outcomes. Little attention has been paid to the potential phenotypic consequences of germline genetic variation on downstream genes. We determined the germline status of 16 well-characterized functional polymorphisms in 126 children with newly diagnosed acute lymphoblastic leukemia (ALL). We assessed whether global gene expression profiles of diagnostic ALL blasts from the same patients differed by these germline polymorphic genotypes. Gene expression values were adjusted for ALL-subtype-specific patterns. Of the 16 loci, only the UGT1A1 promoter repeat polymorphism [A(TA)nTAA] (UGT1A1*28) and GSTM1 deletion were significant predictors of global gene expression in a supervised approach, which divided patients based on their germline genotypes [UGT1A1: 124 probe sets, false discovery rate (FDR)=13%, P< or =0.0031; GSTM1: 112 probe sets, FDR=42.5%, P< or =0.0084]. Genes whose expression distinguished the UGT1A1 (TA) 7/7 genotype from the other UGT1A1 genotypes included HDAC1, RELA and SLC2A1; those that distinguished the GSTM1 null genotype from non-null genotype included NBS1 and PRKR. In an unsupervised approach, the gene expression profiles using the entire array delineated two major clusters of patients. The only germline genotype frequency that differed between the two clusters was UGT1A1 (P=0.002; Fisher's exact test). Although their expression is limited to specific tissues, both GSTM1 and UGT1A1 are involved in the conjugation (and thus transport, excretion and lipophilicity) of a broad range of endobiotics and xenobiotics, which could plausibly have consequences for gene expression in different tissues.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857854     DOI: 10.1093/hmg/ddi170

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  4 in total

Review 1.  The pharmacogenetics research network: from SNP discovery to clinical drug response.

Authors:  K M Giacomini; C M Brett; R B Altman; N L Benowitz; M E Dolan; D A Flockhart; J A Johnson; D F Hayes; T Klein; R M Krauss; D L Kroetz; H L McLeod; A T Nguyen; M J Ratain; M V Relling; V Reus; D M Roden; C A Schaefer; A R Shuldiner; T Skaar; K Tantisira; R F Tyndale; L Wang; R M Weinshilboum; S T Weiss; I Zineh
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

2.  Population-specific GSTM1 copy number variation.

Authors:  R Stephanie Huang; Peixian Chen; Steve Wisel; Shiwei Duan; Wei Zhang; Edwin H Cook; Soma Das; Nancy J Cox; M Eileen Dolan
Journal:  Hum Mol Genet       Date:  2008-10-23       Impact factor: 6.150

3.  Association between the NBS1 E185Q polymorphism and cancer risk: a meta-analysis.

Authors:  Meixia Lu; Jiachun Lu; Xiaobo Yang; Miao Yang; Hao Tan; Bai Yun; Luyuan Shi
Journal:  BMC Cancer       Date:  2009-04-24       Impact factor: 4.430

4.  Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs.

Authors:  Deborah French; Wenjian Yang; Leo H Hamilton; Geoffrey Neale; Yiping Fan; James R Downing; Nancy J Cox; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.